Hans-jochem Prof Dr Kolb

Hans-jochem Prof Dr Kolb's AcademicInfluence.com Rankings

Philosophy

#9071

World Rank

#12572

Historical Rank

Logic

#6067

World Rank

#7548

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Why Is Hans-jochem Prof Dr Kolb Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Hans-jochem Prof Dr Kolb's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Graft-versus-leukemia reactions after bone marrow transplantation. (1990) (2764)
Donor Leukocyte Transfusions for Treatment of Recurrent Chronic Myelogenous Leukemia in Marrow Transplant Patients (1990) (780)
Graft-versus-leukemia effects of transplantation and donor lymphocytes. (2008) (584)
Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. (2009) (565)
Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. (1994) (454)
Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. (2007) (416)
Graft-versus-leukemia reactions in allogeneic chimeras. (2004) (404)
Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML) (2012) (401)
Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. (2005) (379)
Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. (2006) (354)
Interstitial pneumonitis after bone marrow transplantation. Assessment of risk factors. (1986) (351)
A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease. (2008) (309)
The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2. (2005) (271)
Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. (2014) (269)
Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. (2011) (255)
Malignant Neoplasms in Long-Term Survivors of Bone Marrow Transplantation (1999) (242)
Health and Functional Status of Long-Term Survivors of Bone Marrow Transplantation (1997) (216)
Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells. (2010) (215)
Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. The German CML Study Group. (1993) (211)
Microangiopathy in patients on cyclosporine prophylaxis who developed acute graft-versus-host disease after HLA-identical bone marrow transplantation. (1989) (211)
Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. (2010) (208)
Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants (2017) (189)
Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose. (2002) (179)
Safety of retroviral gene marking with a truncated NGF receptor (2003) (168)
Proteomics applied to the clinical follow-up of patients after allogeneic hematopoietic stem cell transplantation. (2004) (168)
Secondary leukaemia and myelodysplasia after autografting for lymphoma: results from the EBMT (1999) (162)
Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: a retrospective study from the lymphoma working party of the European group for blood and marrow transplantation. (2009) (160)
Adoptive immunotherapy with donor lymphocyte transfusions. (1997) (155)
Matched unrelated or matched sibling donors result in comparable survival after allogeneic stem-cell transplantation in elderly patients with acute myeloid leukemia: a report from the cooperative German Transplant Study Group. (2008) (147)
Comparison of graft-versus-host-disease and survival after HLA-identical sibling bone marrow transplantation in ethnic populations. (2005) (144)
Proteomic patterns predict acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. (2007) (144)
Evidence of Peripheral Blood‐Derived, Plastic‐Adherent CD34−/low Hematopoietic Stem Cell Clones with Mesenchymal Stem Cell Characteristics (2000) (142)
Impact of human herpesvirus‐6 after haematopoietic stem cell transplantation (2005) (140)
Second allograft for hematologic relapse of acute leukemia after first allogeneic stem-cell transplantation from related and unrelated donors: the role of donor change. (2013) (128)
MARROW GRAFTS BETWEEN DL‐A‐MATCHED CANINE LITTERMATES (1973) (119)
MARROW GRAFTS BETWEEN DL‐A‐MATCHED CANINE LITTERMATES (1973) (119)
Survival with bone marrow transplantation versus hydroxyurea or interferon for chronic myelogenous leukemia. The German CML Study Group. (1998) (118)
Hemostatic complications in bone marrow transplantation: a retrospective analysis of 447 patients (2002) (114)
Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia. (2007) (113)
The effect of prior exposure to imatinib on transplant-related mortality. (2006) (112)
NCI First International Workshop on The Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Biology Underlying Recurrence of Malignant Disease following Allogeneic HSCT: Graft-versus-Tumor/Leukemia Reaction. (2010) (105)
Allogeneic transplantation versus chemotherapy as postremission therapy for acute myeloid leukemia: a prospective matched pairs analysis. (2014) (100)
High-Dose Therapy and Autologous Stem-Cell Transplantation in Angioimmunoblastic Lymphoma: Complete Remission at Transplantation Is the Major Determinant of Outcome—Lymphoma Working Party of the European Group for Blood and Marrow Transplantation (2008) (98)
Interferon-alpha before allogeneic bone marrow transplantation in chronic myelogenous leukemia does not affect outcome adversely, provided it is discontinued at least 90 days before the procedure. (1999) (88)
Blockade of BCL-2 proteins efficiently induces apoptosis in progenitor cells of high-risk myelodysplastic syndromes patients (2016) (86)
Detection of minimal residual disease in unselected patients with acute myeloid leukemia using multiparameter flow cytometry for definition of leukemia-associated immunophenotypes and determination of their frequencies in normal bone marrow. (2003) (86)
Randomized comparison of interferon α and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon α and hydroxyurea (2003) (84)
Cognitive functioning in allogeneic hematopoietic stem cell transplantation recipients and its medical correlates: a prospective multicenter study (2013) (83)
Effect of prior blood transfusions on marrow grafts: abrogation of sensitization by procarbazine and antithymocyte serum. (1974) (80)
Results of Transplanting Bone Marrow from Genetically Identical Twins into Patients with Aplastic Anemia (1997) (78)
Gender aspects in chronic myeloid leukemia: long-term results from randomized studies (2005) (74)
Endothelial Cell–Derived Microparticles in Allogeneic Hematopoietic Stem Cell Recipients (2006) (72)
Neurological and neuroradiological findings in long‐term survivors of allogeneic bone marrow transplantation (1998) (72)
Evaluation of C‐reactive protein, interleukin‐6, and procalcitonin levels in allogeneic hematopoietic stem cell recipients (2006) (72)
Leukemic dendritic cells generated in the presence of FLT3 ligand have the capacity to stimulate an autologous leukemia-specific cytotoxic T cell response from patients with acute myeloid leukemia (2001) (70)
A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation. (2006) (65)
Inflammatory reactions induced by pretransplant conditioning--an alternative target for modulation of acute GvHD and complications following allogeneic bone marrow transplantation? (1997) (65)
Adoptive immunotherapy in canine chimeras. (1997) (64)
Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV (2016) (63)
ANTILYMPHOCYTIC ANTIBODIES AND MARROW RANSPLANTATION: VI. GRAFT‐VERSUS-HOST TOLERANCE IN DLA‐INCOMPATIBLE DOGS AFTER IN VITRO TREATMENT OF BONE MARROW WITH ABSORBED ANTITHYMOCYTE GLOBULIN (1979) (62)
Dendritic Cells (DCs) Can Be Successfully Generated From Leukemic Blasts in Individual Patients With AML or MDS: An Evaluation of Different Methods (2010) (60)
Allorestricted T cells with specificity for the FMNL1-derived peptide PP2 have potent antitumor activity against hematologic and other malignancies. (2007) (59)
Ex vivo generation of cytotoxic T lymphocytes specific for one or two distinct viruses for the prophylaxis of patients receiving an allogeneic bone marrow transplant (2001) (59)
Impaired expression of the CD3‐zeta chain in peripheral blood T cells of patients with chronic myeloid leukaemia results in an increased susceptibility to apoptosis (2000) (58)
Immunologic Reactivity in Canine Marrow Graft Recipients (1974) (58)
Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV (2013) (57)
The impact of antithymocyte globulin on short-term toxicity after allogeneic stem cell transplantation (2002) (56)
Noncytotoxic alkyl‐lysophospholipid treatment increases sensitivity of leukemic K562 cells to lysis by natural killer (NK) cells (1996) (55)
Canine embryo-derived stem cells and models for human diseases. (2008) (55)
Allogeneic transplantation as post-remission therapy for cytogenetically high-risk acute myeloid leukemia: landmark analysis from a single prospective multicenter trial (2011) (55)
Low- versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignancies. (1999) (54)
Canine Embryo‐Derived Stem Cells—Toward Clinically Relevant Animal Models for Evaluating Efficacy and Safety of Cell Therapies (2007) (53)
Virus infection in HLA-haploidentical hematopoietic stem cell transplantation: incidence in the context of immune recovery in two different transplantation settings (2015) (52)
Mitoxantrone therapy in multiple sclerosis and acute leukaemia: a case report out of 644 treated patients (2004) (50)
Hematopoietic reconstitution of syngeneic mice with a peripheral blood-derived, monoclonal CD34-, Sca-1+, Thy-1(low), c-kit+ stem cell line. (1999) (50)
High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of Outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. (2008) (50)
Treatment of established graft-versus-host disease in dogs by antithymocyte serum or prednisone. (1973) (49)
Immunotherapy of recurrent B-cell malignancies after allo-SCT with Bi20 (FBTA05), a trifunctional anti-CD3 × anti-CD20 antibody and donor lymphocyte infusion (2009) (49)
Joint report of the Third International Workshop on Canine Immunogenetics. I. Analysis of homozygous typing cells. (1986) (47)
An epithelial cell line with elongated myoid morphology derived from bovine mammary gland. Expression of cytokeratins and desmosomal plaque proteins in unusual arrays. (1983) (46)
Diagnosis of Hepatic Veno-occlusive Disease by Plasminogen Activator Inhibitor-1 Plasma Antigen Levels: A Prospective Analysis in 350 Allogeneic Hematopoietic Stem Cell Recipients (2005) (43)
Intravenous ribavirin for eradication of respiratory syncytial virus (RSV) and adenovirus isolates from the respiratory and/or gastrointestinal tract in recipients of allogeneic hematopoietic stem cell transplants. (2004) (42)
Fractionated total body irradiation and autologous bone marrow transplantation in dogs: hemopoietic recovery after various marrow cell doses. (1980) (41)
Donor leukocyte transfusions for leukemic relapse (1995) (41)
Hematopoietic stem cell transplantation after reduced-intensity conditioning as treatment of sickle cell disease. (2002) (41)
Mesenchymal stromal cells for treatment of steroid-refractory GvHD: a review of the literature and two pediatric cases (2011) (38)
Transforming growth factor beta-1 released from platelets contributes to hypercoagulability in veno-occlusive disease following hematopoetic stem cell transplantation. (2005) (38)
Interferon alpha in combination with GM-CSF induces the differentiation of leukaemic antigen-presenting cells that have the capacity to stimulate a specific anti-leukaemic cytotoxic T-cell response from patients with chronic myeloid leukaemia. (2000) (38)
Immunotherapy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation: study protocol of an investigator-driven, open-label, non-randomized, uncontrolled, dos (2013) (36)
Cellular immunotherapy after allogeneic stem cell transplantation in hematologic malignancies (2004) (36)
Comparison of matched sibling donors versus unrelated donors in allogeneic stem cell transplantation for primary refractory acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT (2017) (35)
European experience and risk factor analysis of donor cell-derived leukaemias/MDS following haematopoietic cell transplantation (2018) (35)
Randomized Comparison of Interferon-a With Busulfan and Hydroxyurea in Chronic Myelogenous Leukemia (2002) (34)
Interferon alpha in combination with GM‐CSF induces the differentiation of leukaemic antigen‐presenting cells that have the capacity to stimulate a specific anti‐leukaemic cytotoxic T‐cell response from patients with chronic myeloid leukaemia (2000) (34)
Risk assessment in patients with Ph+ chronic myelogenous leukemia at first relapse after allogeneic stem cell transplant: an EBMT retrospective analysis. The Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. (2000) (34)
Pathology of acute graft-versus-host disease in the dog. An autopsy study of ninety-five dogs. (1979) (34)
Impact of Thrombophilic Gene Mutations and Graft-versus-Host Disease on Thromboembolic Complications after Allogeneic Hematopoietic Stem-Cell Transplantation (2004) (33)
PUVA-bath photochemotherapy and isotretinoin in sclerodermatous graft-versus-host disease. (2008) (33)
Antithymocyte serum and methotrexate for control of graft-versus-host disease in dogs. (1973) (33)
Antithymocyte serum and methotrexate for control of graft-versus-host disease in dogs. (1973) (33)
Randomized Comparison of Imatinib 800 Mg Vs. Imatinib 400 Mg +/- IFN in Newly Diagnosed BCR/ABL Positive Chronic Phase CML: Analysis of Molecular Remission at 12 Months; The German CML-Study IV. (2009) (32)
Quality of T-cells after stimulation with leukemia-derived dendritic cells (DC) from patients with acute myeloid leukemia (AML) or myeloid dysplastic syndrome (MDS) is predictive for their leukemia cytotoxic potential. (2010) (32)
Successful Subtype Oriented Treatment Strategies in Adult T-All; Results of 744 Patients Treated in Three Consecutive GMALL Studies. (2009) (31)
Influence of molecular subgroups on outcome of acute myeloid leukemia with normal karyotype in 141 patients undergoing salvage allogeneic stem cell transplantation in primary induction failure or beyond first relapse (2013) (31)
Prevention of graft-versus-host disease by immunosuppressive agents after transplantation of DLA-nonidentical canine marrow. (1986) (29)
Selection of CMV‐specific CD8+ and CD4+ T cells by mini‐EBV‐transformed B cell lines (2005) (28)
Is a Recurrent Abnormality in Chronic and Acute Leukemia that Fuses PCM 1 to JAK 2 (2005) (28)
Treatment of steroid-resistant acute GVHD with OKT3 and high-dose steroids results in better disease control and lower incidence of infectious complications when compared to high-dose steroids alone: a randomized multicenter trial by the EBMT Chronic Leukemia Working Party (2007) (28)
Clofarabine‐containing conditioning regimen for allo‐SCT in AML/ALL patients: a survey from the Acute Leukemia Working Party of EBMT (2012) (27)
The changing scene of allogeneic stem cell transplantation for chronic myeloid leukemia—a report from the German Registry covering the period from 1998 to 2004 (2009) (26)
The detection of apoptosis in a human in vitro skin explant assay for graft versus host reactions. (2002) (26)
Impact of genomic risk factors on outcome after hematopoietic stem cell transplantation for patients with chronic myeloid leukemia (2010) (26)
Immune reactivity in dogs with spontaneous malignancy. (1974) (26)
Allogeneic stem-cell transplantation provides excellent results in advanced stage chronic myeloid leukemia with major cytogenetic response to pre-transplant imatinib therapy (2007) (26)
One-way nonstimulation in MLC related to DL-A homozygosity. (1973) (26)
Efficacy and Pharmacologic Data of Second-Generation Tyrosine Kinase Inhibitor Nilotinib in BCR-ABL-Positive Leukemia Patients with Central Nervous System Relapse after Allogeneic Stem Cell Transplantation (2014) (25)
OKT3 muromonab as second-line and subsequent treatment in recipients of stem cell allografts with steroid-resistant acute graft-versus-host disease (2005) (25)
High-risk additional chromosomal abnormalities at low blast counts herald death by CML (2020) (25)
Hematopoietic stem cell transplantation and cellular therapy (2017) (25)
Minor Histocompatibility Antigens on Canine Hemopoietic Progenitor Cells1 (2003) (25)
A clinical cohort trial of antifungal combination therapy: efficacy and toxicity in haematological cancer patients (2008) (25)
Dose rate and dose fractionation studies in total body irradiation of dogs. (1979) (24)
Kinetics of dendritic cell chimerism and T cell chimerism in allogeneic hematopoietic stem cell recipients (2006) (23)
Tolerance and chimerism1 (2003) (22)
Adoptive Immunotherapy in Chimeras with Donor Lymphocytes (2003) (22)
Adoptive immunotherapy in human and canine chimeras--the role of interferon alfa. EBMT Chronic Leukemia Working Party. (1993) (21)
Identification of four MLC-specificities in the dog. (2008) (20)
Occurrence, risk factors and outcome of adenovirus infection in adult recipients of allogeneic hematopoietic stem cell transplantation. (2016) (20)
Randomized study of the combination of hydroxyurea and interferon alpha versus hydroxyurea monotherapy during the chronic phase of chronic myelogenous leukemia (CML Study II). The German CML Study Group. (1996) (20)
Human parvovirus B19-associated disease in bone marrow transplantation (1999) (20)
Activation of protein kinase A (PKA) by 8-Cl-cAMP as a novel approach for antileukaemic therapy (2004) (19)
In-vivo generation of leukaemia-derived dendritic cells. (2004) (19)
Bone marrow involvement identifies a subgroup of advanced Ewing sarcoma patients with fatal outcome irrespective of therapy in contrast to curable patients with multiple bone metastases but unaffected marrow (2016) (19)
Factor XIII activity levels in patients with allogeneic haematopoietic stem cell transplantation and acute graft‐versus‐host disease of the gut (2002) (19)
GENETIC VARIATION OF RED BLOOD CELL ENZYMES IN THE DOG: USE OF SOLUBLE GLUTAMIC OXALOACETIC TRANSAMINASE AS PROOF OF CHIMERISM (1974) (19)
THE EFFECT OF BUFFY COAT‐POOR BLOOD TRANSFUSION ON SUBSEQUENT HEMOPOIETIC GRAFTS (1973) (18)
Various 'dendritic cell antigens' are already expressed on uncultured blasts in acute myeloid leukemia and myelodysplastic syndromes. (2011) (18)
Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV (2018) (18)
CD4(+)and CD8(+)T-cell reactions against leukemia-associated- or minor-histocompatibility-antigens in AML-patients after allogeneic SCT. (2014) (18)
Canine embryonic stem cells: state of the art. (2010) (18)
Allogeneic stem cell transplantation as a new treatment option for patients with severe Bernard-Soulier Syndrome (2006) (18)
Microparticles for Diagnosis of Graft-Versus-Host Disease After Allogeneic Stem Transplantation (2011) (18)
Graft versus leukemia effect after haploidentical HSCT in a MLL‐negative infant AML with HLXB9/ETV6 rearrangement (2008) (18)
Quiescence of CD34-negative haematopoietic stem cells is mediated by downregulation of Cyclin B and no stat activation. (2000) (17)
Emerging Role of Mesenchymal Stromal Cell-Derived Extracellular Vesicles in Pathogenesis of Haematological Malignancies (2019) (17)
The German CML study, comparison of busulfan vs. hydroxyurea vs. interferon alpha and establishment of prognostic score 1. (1993) (17)
Randomised placebo controlled study of RH-GM-CSF following ALG in the treatment of aplastic anaemia. (1991) (17)
Allogeneic bone marrow transplantation in leukemia. (1984) (17)
Hematopoietic transplantation: State of the art (1997) (16)
Molecular Response to First Line Imatinib Therapy Is Predictive for Long Term Event Free Survival in Patients with Chronic Phase Chronic Myelogenous Leukemia – An Interim Analysis of the Randomized German CML Study IV (2008) (16)
Chronic myeloid leukemia in the elderly: long-term results from randomized trials with interferon alpha. (2003) (16)
Chronic myeloid leukemia in the elderly: long-term results from randomized trials with interferon α (2003) (15)
Adoptive immunotherapy in human and canine chimeras. (1993) (15)
Endothelial cells but not epithelial cells or cardiomyocytes are partially replaced by donor cells after allogeneic bone marrow and stem cell transplantation. (2003) (15)
Huge splicing frequency in human Y chromosomal UTY gene. (2011) (15)
Influence of polymorphism within the heme oxygenase-I promoter on overall survival and transplantation-related mortality after allogeneic stem cell transplantation. (2008) (15)
Vaccination against B-cell chronic lymphocytic leukemia with trioma cells: preclinical evaluation. (2003) (14)
THE EFFECT OF PRIOR BLOOD TRANSFUSIONS ON HEMOPOIETIC GRAFTS FROM HISTOINCOMPATIBLE CANINE LITTERMATES (1972) (14)
Prediction of Molecular Response of Chronic Phase CML Patients by the EUTOS Score: Results of the Randomized CML-Study IV, (2011) (14)
Prevention and treatment of relapse after stem cell transplantation by cellular therapies (2018) (13)
Ponatinib given for advanced leukemia relapse after allo-SCT (2015) (13)
Idarubicin monotherapy in multiply pretreated leukemia patients: response in relation to P-glycoprotein expression (1997) (13)
Prevention of graft-versus-host disease in DLA-haplotype mismatched dogs and hemopoietic engraftment of CD6-depleted marrow with and without cG-CSF treatment after transplantation. (1994) (13)
Molecular and Cytogenetic Response After 3 Months of Imatinib Treatment Is Predictive for the Risk of Disease Progression and Death in Newly Diagnosed Chronic Myeloid Leukemia Patients – a Follow-up Analysis of the German CML Study IV (2011) (13)
Detection of minimal residual disease in unselected patients with acute myeloid leukemia using multiparameter flow cytometry to define leukemia-associated immunophenotypes and determine their frequencies in normal bone marrow (2003) (13)
Late effects after allogeneic bone marrow transplantation (1997) (13)
Surveillance of megakaryocytic function by measurement of CD61‐exposing microparticles in allogeneic hematopoietic stem cell recipients (2011) (12)
Identification and characterization of a mouse monoclonal antibody (M10) directed against canine (dog) CD8+ lymphocytes. (1993) (12)
Bispecific antibody fragments with CD20 X CD28 specificity allow effective autologous and allogeneic T-cell activation against malignant cells in peripheral blood and bone marrow cultures from patients with B-cell lineage leukemia and lymphoma. (1999) (12)
Dose rate and fractionation of total body irradiation in dogs: short and long term effects. (1990) (12)
Randomized Comparison of Imatinib 400 Mg Vs. Imatinib + IFN Vs. Imatinib + AraC Vs. Imatinib after IFN Vs. Imatinib 800 Mg: Optimized Treatment and Survival. Designed First Interim Analysis of the German CML Study IV (2008) (12)
Expression of HSV-TK suicide gene in primary T lymphocytes: the dog as a preclinical model. (2000) (12)
The role of soluble and cell-surface expressed 4-1BB ligand in patients with malignant hemopoietic disorders (2009) (11)
Leukocyte Transfusions for the Modification of Host-versus-graft Reactions in Dogs (1978) (11)
CD34-Negative Hematopoietic Stem Cells Isolated from Human Peripheral Blood Cells as Ultimate Precursors of Hematopoietic Progenitors (1997) (11)
Molecular Response After 3 Months of 1st Line Imatinib Therapy Is Predictive for Treatment Failure and Disease Progression In Patients with Chronic Phase Chronic Myeloid Leukemia - a Follow-up Analysis of the German CML Study IV (2010) (11)
Improved effector function of leukemia-specific T-lymphocyte clones trained with AML-derived dendritic cells. (2008) (11)
Hyperfractionation of total-body irradiation and engraftment of marrow from DLA-haploidentical littermates. (1987) (11)
Canine-DCs using different serum-free methods as an approach to provide an animal-model for immunotherapeutic strategies. (2010) (11)
WT1, PRAME, and PR3 mRNA Expression in Acute Myeloid Leukemia (AML) (2020) (11)
Serum Chemokine-release Profiles in AML-patients Might Contribute to Predict the Clinical Course of the Disease (2019) (11)
Cytogenetic response to prior treatment with interferon-α is predictive for survival after allogeneic hematopoietic stem cell transplantation in chronic myeloid leukemia (2006) (11)
DLI: Where are we know? (2005) (11)
Bone marrow transplantation in DLA-haploidentical canine littermates: fractionated total body irradiation (FTBI) and in vitro treatment of the marrow graft with anti-T-cell globulin (ATCG). (1980) (10)
Marrow grafts in LD--SD typed dogs treated with cyclophosphamide. (1976) (10)
EFFECT OF TIME ON SENSITIZATION TO HEMOPOIETIC GRAFTS BY PRECEDING BLOOD TRANSFUSION (1975) (10)
RESCUE FROM CANINE GRAFT‐VERSUS-HOST REACTION BY AUTOLOGOUS OR DL‐A-COMPATIBLE MARRO,W (1974) (10)
RESCUE FROM CANINE GRAFT‐VERSUS-HOST REACTION BY AUTOLOGOUS OR DL‐A-COMPATIBLE MARRO,W (1974) (10)
RECOGNITION OF TWO EPITOPES OF AN ANTIGEN PRESENT ON CANINE T CELLS BUT NOT ON HEMOPOIETIC PROGENITORS BY FOUR MONOCLONAL ANTIBODIES (1988) (10)
Meeting report: Vienna 2008 Workshop of the German–Austrian Working Group for Studying Prognostic Factors in Myelodysplastic Syndromes (2009) (10)
Spontaneous tumor cell cytotoxicity mediated by peripheral blood mononuclear leukocytes of the dog. (1993) (10)
In vitro-induced response patterns of antileukemic T cells: characterization by spectratyping and immunophenotyping (2013) (10)
Marrow grafts in LD--SD typed dogs treated with cyclophosphamide. (1976) (10)
Role of Interferon (IFN)&agr; in “Cocktails” for the Generation of (Leukemia-derived) Dendritic Cells (DCleu) From Blasts in Blood From Patients (pts) With Acute Myeloid Leukemia (AML) and the Induction of Antileukemic Reactions (2019) (9)
Peripheral Dendritic Cell Chimerism in Allogeneic Hematopoietic Stem Cell Recipients (2005) (9)
Marrow grafts between histoincompatible canine family members. (1972) (9)
The FLAMSA concept—past and future (2020) (9)
Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in the Imatinib-Era: Update on the Survival Outcome Following Allogeneic HSCT after Imatinib Failure; Results of the German CML Study IV (2008) (9)
Polymorphism of the fourth complement component in the dog and linkage to the DLA System (2004) (9)
The Vigor of Defense Against Non-Self: Potential Superiority of Allorestricted T Cells in Immunotherapy of Cancer? (2013) (9)
Marrow grafts between histoincompatible canine family members. (1972) (9)
The German competence network ‘Acute and chronic leukemias’ (2004) (8)
Graft-versus-host disease (GVHD) following marrow grafts from DLA-matched canine littermates. (1979) (8)
Canine marrow grafts in donor-recipient combinations with one-way nonstimulation in mixed lymphocyte culture. (1975) (8)
Canine marrow grafts in donor-recipient combinations with one-way nonstimulation in mixed lymphocyte culture. (1975) (8)
Randomized Comparison of Primary Allogeneic Stem Cell Transplantation and Best Available Drug Treatment in Chronic Myeloid Leukemia. (2006) (8)
Graft-versus-host disease (GVHD) following marrow grafts from DLA-matched canine littermates. (1979) (8)
Histological correlation between different centers using the skin explant model to predict graft-versus-host disease following bone marrow transplantation. (2001) (8)
Canine Long-Term Bone Marrow Culture Neutrophil Production and Functionality (2004) (7)
A Distinct Pattern of Non-HLA Polymorphisms Predicts an Increased Risk for GvHD without Benefit of GvL in HLA Matched Sibling Transplants for Chronic Myeloid Leukemia (CML). (2006) (7)
Improved Outcome for Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) with Poor Risk Cytogenetics – Result from An Analysis on 172 Patients Receiving FLAMSA-RIC Conditioning for Allogeneic Stem Cell Transplantatioin (SCT). (2008) (7)
Stem cell transplants for patients with relapsed/refractory leukaemia (2009) (7)
Secondary Malignancies in CML Patients – Data From the German CML Study IV (2012) (7)
Donor lymphocyte infusions in adolescents and young adults for control of advanced pediatric sarcoma (2018) (7)
Allogeneic Stem Cell Transplantation for MDS and sAML Following Reduced Intensity Conditioning and Preemptive Donor Lymphocyte Transfusion. (2006) (7)
Randomized study on the treatment of chronic myeloid leukemia (CML) in chronic phase with busulfan versus hydroxyurea versus interferon-alpha (1988) (7)
Bone Loss after Allogeneic Haematopoietic Stem Cell Transplantation: A Pilot Study on the Use of Zoledronic Acid (2012) (7)
Recovery from CMV esophagitis after allogeneic bone marrow transplantation using non-myeloablative conditioning: the role of immunosuppression. (2005) (7)
Cytokine Release Patterns in Mixed Lymphocyte Culture (MLC) of T-Cells with Dendritic Cells (DC) Generated from AML Blasts Contribute to Predict anti-Leukaemic T-Cell Reactions and Patients’ Response to Immunotherapy (2015) (7)
Immune phenotype of canine hematopoietic progenitor cells. (1997) (7)
Determination of donor-type chimerism using a semi-quantitative PCR-based method in a canine model for bone marrow transplantation. (2002) (6)
Outcome of Patients with Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Beyond First Complete Remission (CR1) (2018) (6)
Immunobiology of Bone Marrow Transplantation (1980) (6)
Splenic irradiation before hematopoietic stem cell transplantation for chronic myeloid leukemia: long-term follow-up of a prospective randomized study (2016) (6)
Malignant Neoplasms in Long-Term Survivors of Bone Marrow Transplantation – Follow up (2008) (6)
Risk Factors of HLA-Haploidentical Transplantation Using the Combination of Unmodified Marrow and CD6-Depleted G-CSF Mobilized Blood Cells. (2005) (6)
NK activity of canine blood and marrow cells. (1994) (6)
[Allogeneic skin transplantation in chronic graft-versus-host disease following bone marrow transplantation]. (1990) (5)
Virus-specific T cells for therapy--approaches, problems, solutions. (2012) (5)
Optimaization of Imatinib Therapy by Combination. 5 Year Survival and Response Results of the Pilot Phase of the Randomized German CML STUDY IV. (2009) (5)
In vitro generation of mature neutrophils from canine Lin- bone marrow cells. (2005) (5)
[Allogeneic stem cell transplantation in the management of acute myeloid leukemia]. (2007) (5)
Bone Marrow Transplantation in DLA-Haploidentical Canine Littermates (1980) (5)
A Randomized Single−Blind Study of Extracorporeal Photopheresis with UVADEX® Plus Conventional Therapy (CT) Compared to CT Alone in Chronic GVHD. (2006) (5)
Anti‐leukaemic activity of a novel haploidentical‐transplantation approach employing unmanipulated bone marrow followed by CD6‐depleted peripheral blood stem cells in children with refractory/relapsed acute leukaemia (2013) (5)
Durable Remission after Prophylactic Donor Lymphocyte Transfusion Following Allogeneic Stem Cell Transplantation with Reduced Conditioning for High-Risk AML and MDS. (2004) (5)
[Bone marrow transplantation in adults in acute leukemia, aplastic anemia and paroxysmal nocturnal hemoglobinuria. Results of the Medical Clinic IIi of LMU (Ludwig-Maximilians University) Munich]. (1983) (5)
Mast cells and GVHD: old cells with a new role. (2013) (5)
Complete Molecular Remission (CMR 4.5) of CML Is Induced Faster by Dose – Optimized Imatinib and Predicts Better Survival - Results From the Randomized CML-Study IV (2012) (5)
Therapeutic progress and comparative aspects in chronic myelogenous leukemia (CML): interferon alpha vs. hydroxyurea vs. busulfan and expression of MMTV-related endogenous retroviral sequences in CML. German CML Study Group. (1994) (5)
Prospective Evaluation of An Agvhd-Specific Proteomic Pattern in More Than 340 Patients. (2009) (5)
Combined immunophenotyping and fluorescence in situ hybridization with chromosome-specific DNA probes allows quantification and differentiation of ex vivo generated dendritic cells, leukemia-derived dendritic cells and clonal leukemic cells in patients with acute myeloid leukemia (2013) (4)
Immunological characterization of canine hematopoietic progenitor cells (1991) (4)
In vitro‐generated stem cell leukaemia showing altered cell cycle progression with distinct signalling of the tyrosine‐phosphorylated rasGAP‐associated p62dok protein (2000) (4)
Interferon in chronic myeloid leukemia (1993) (4)
Randomized studies with interferon in chronic myelogenous leukemia (CML) and comparative molecular aspects. German CML Study Group. (1997) (4)
Tolerance in DLA-haploidentical canine littermates following CD6-depleted marrow transplantation and donor lymphocyte transfusion. (2009) (4)
Explaining survival differences between two consecutive studies with allogeneic stem cell transplantation in patients with chronic myeloid leukemia (2014) (4)
CD6-depleted mobilized stem cells for modification of HVG and GVH reactions after HLA-haploidentical marrow transplantation (2005) (4)
A Randomized Prospective Multicenter Phase III Trial Comparing Standard GvHD Prophylaxis with Cyclosporine and Methotrexate with Additional Pretransplant ATG Fresenius (ATG-F) in Allogeneic Stem Cell Transplantation from Matched Unrelated Donors (2008) (4)
Canine stem cell factor augments expression of matrix metalloproteinase-9 by CD34 cells. (2008) (4)
Rat monoclonal antibodies against three different epitopes of the canine Thy-1 and their depletion capacity in vivo. (1994) (4)
High-Risk Additional Chromosomal Abnormalities in CML Herald Death By Blast Crisis Already at Low Blast Levels (2019) (3)
Transplantation of CD6-depleted peripheral blood stem cells after DLA-haploidentical bone marrow transplantation contributes to engraftment and tolerance in a preclinical model of stem cell transplantation. (2011) (3)
COMPARISON OF GRAFT-VS-HOST-DISEASE AND SURVIVAL AFTER HLA- IDENTICAL SIBLING BONE MARROW TRANSPLANTATION IN DIFFERENT ETHNIC POPULATIONS Running Head: Graft-vs-host disease in ethnic populations For Submission to BLOOD, Clinical Observations (2004) (3)
In vitro and in vivo immune response to specific antigens in canine marrow graft recipients. (1977) (3)
Graft versus host tolerance in dogs across one DLA-haplotype by depletion of CD6 positive cells. (1992) (3)
As time goes by... (2015) (3)
Spindle bridge and mid-body in cultured lymphocytes. (1968) (3)
Adoptive Immunotherapy in Stem Cell Transplantation (2004) (3)
Functional characterization of canine lymphocyte subsets (1991) (3)
Studies on canine bone marrow long-term culture: effect of stem cell factor. (1998) (3)
Time-Related Interpretation of Molecular Response Levels According to Long Term Overall and Progression-Free Survival of CML Patients on First-Line Imatinib Treatment (2011) (3)
Therapeutic progress and comparative aspects in chronic myelogenous leukemia (CML) : interferon alpha vs. hydroxyurea vs. busulfan and expression of MMTV-related endogenous retrovival sequences in CML (1994) (3)
The influence of glucocorticoid receptor single nucleotide polymorphisms on outcome after haematopoietic stem cell transplantation (2018) (3)
Interstitial Pneumonitis After Bone Marrow Transplantation (2020) (2)
Correction: High-risk additional chromosomal abnormalities at low blast counts herald death by CML (2020) (2)
CD6-Depleted Mobilized Stem Cells for Modification of HVG and GVH Reactions after HLA-Haploidentical Marrow Transplantation. (2004) (2)
The diallelic locus encoding the minor histocompatibility antigen HA-1 is evolutionarily conserved. (2006) (2)
[Which patients drop out of psychiatric out-patient treatment (author's transl)]. (1980) (2)
Paramunity-inducing Factors (PINDs) in dendritic cell (DC) cultures lead to impaired antileukemic functionality of DC-stimulated T-cells. (2018) (2)
Kidney transplantation following treatment with cyclophosphamide and bone marrow grafting. (1977) (2)
Retrospective Comparison of Using or Not Using Donor Lymphocyte Transfusion in the Treatment of Hematological Relapse after Allogeneic Stem Cell Transplantation in 489 Adults with Acute Myeloid Leukemia. (2004) (2)
Shift to a New Donor Does Not Improve the Outcome After Second Allogeneic Stem Cell Transplantation (alloSCT) in Acute Leukemia Relapse After a First Allosct – a Risk Factor Analysis by the German Stem Cell Registry (DRST). (2009) (2)
Comparable Outcome after Allogeneic Hematopoietic Cell Transplantation from Matched Unrelated and Sibling Donors in Elderly Patients with Acute Myeloid Leukemia - Results of a Retrospective Analysis in 368 Patients. (2007) (2)
Infection and GVHD (2018) (2)
ASSESSMENT OF IMATINIB 400MG AS FIRST LINE TREATMENT OF CHRONIC MYELOID LEUKEMIA: 10-YEAR SURVIVAL RESULTS OF THE RANDOMIZED CML STUDY IV (2017) (2)
[Radiobiologic considerations about further development of whole-body irradiation with subsequent bone marrow transplantation applied during the treatment of acute leukemia (author's transl)]. (1981) (2)
Chronic myelogenous leukemia: recent developments in prognostic evaluation and chemotherapy. The German CML Study Group. (1992) (2)
Interferon in chronic myeloid leukemia. A workshop report. (1993) (2)
Conversion of AML-blasts to leukemia-derived dendritic cells (DCleu) in 'DC-culture-media' shifts correlations of released chemokines with antileukemic T-cell reactions. (2021) (1)
Mosaicism in BCR‐ABL protein expression in B cells in chronic meylogenous leukemia (1996) (1)
Serological identification and separation of canine lymphocyte subpopulations. (1984) (1)
Allogeneic Stem Cell Transplantation (SCT) with Reduced Intensity Conditioning (RIC) Immediately After Intensive Cytoreduction for High-Risk Myeloid Leukemias (2003) (1)
Prognostic Factors Identified Via a Cox Proportional Hazard Cure Model Explain Survival Differences After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Chronic Myeloid Leukemia (CML) Between Two Consecutive Patient Cohorts (2012) (1)
Busulfan (Bu) Plus Cyclophosphamide (Cy) Versus TBI Plus Cy Conditioning for Allogeneic Stem Cell Transplantation (alloSCT) From Matched Unrelated Donors (MUD) In Adult Patients with AML in First Relapse: A Survey From the Acute Leukemia Working Party of EBMT (2011) (1)
Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) with a Related Donor in Chronic Myeloid Leukemia (CML): An Explanation for Fast Improvement of Survival in Two Consecutive German CML Studies. (2009) (1)
Cell-mediated immunity in canine marrow graft recipients given cyclophosphamide. (1978) (1)
Pretreatment Expression Levels of MDR1 and OCT-1 Predict Response to First Line Imatinib Treatment In Chronic Phase CML Patients (2010) (1)
Mosaicicm in bcr-abl protein expression in B cells in chronic myelogenous leukemia. (1996) (1)
Allogeneic Stem Cell Transplantation Versus Conventional Postremission Therapy for Acute Myeloid Leukemia in First Complete Remission: A Matched Pairs Analysis (2012) (1)
Therapeutic Nucleic Acids: A Potential Source of Resistance to Cancer, Antiviral and Immunosuppressive Therapy. (2008) (1)
[Physicians: how might patients see you and how do we see ourselves? A questionnaire concerning the physician-patient relationship]. (1979) (1)
10-year survival with imatinib: final evaluation of randomized CML-study (2017) (1)
Polymorphism in the Promoter Region of the Hemeoxygenase I Gene of the Donor Influences Overall Survival and Graft Versus Host Disease. (2006) (1)
Preliminary evidence for a fourth phosphoglucomutase (PGM) locus in the dog. (1975) (1)
Long Term Follow-up and Matched Pair Analysis of Adjuvant Donor Lymphocyte Transfusions Following Allogeneic Stem Cell Transplantation after Reduced Intensity Conditioning for High-Risk AML. (2008) (1)
27 BLOCKADE OF BCL-2 PROTEINS EFFICIENTLY INDUCES APOPTOSIS IN PROGENITOR CELLS OF HIGH-RISK MYELODYSPLASTIC SYNDROMES (MDS) PATIENTS (2015) (1)
Steroid Refractory GVHD of the Gut Can Be Treated Effectively with Daclizumab and Sirolimus. (2004) (1)
Factors Determining Survival after Unrelated Donor Stem Cell Transplantation in Primary Refractory Acute Myeloid Leukemia (2008) (1)
Distinct Characteristics of e13a2 versus e14a2 BCR-ABL Chronic Myeloid Leukemia under Upfront Treatment with Imatinib – an Analysis of the German CML Study IV, (2011) (1)
Does Microangiopathy Predict Chronic GvHD After Allogeneic Stem Cell Transplantation? A Clinical and Immunohistochemical Study on Bone Marrow Biopsies (2011) (1)
Abstract 2462: MondoA mediatesin vivoaggressiveness of common ALL and may serve as a T-cell immunotherapy target (2016) (1)
Graft-Vs-Leukemia Effects of Allogeneic Stem Cell Transplantation from HLA-Haploidentical Family Members as Compared to HLA-Identical Sibling Donors (2008) (1)
Allogeneic Stem Cell Transplantation with Dose-Reduced Conditioning in Relapsed Follicular and Mantle Cell Lymphoma - A Prospective Phase II Trial of the German Low Grade Lymphoma Study Group (GLSG). (2007) (1)
Prospective Evaluation of Graft-Versus-Host Disease-Specific Proteomics Pattern in Patients after Allogeneic Stem Cell Transplantation. (2005) (1)
Comparison of Matched-Sibling Donors Versus Unrelated Donors in Allogeneic Stem Cell Transplantation (allo-SCT) for Primary Refractory Acute Myeloid Leukemia (PRF AML): A Report of 1041 Patients from the Acute Leukemia Working Party of the EBMT (2015) (1)
Bone Marrow Reaction in Patients with Chronic GvHD - An Immunohistochemical Analysis of Microvessels and Lymphocytes. (2007) (0)
Hemopoietic Progenitor Cells Minor Histocompatibility Antigens on Canine (2003) (0)
Improved Survival with Adjuvant Donor Lymphocyte Transfusions Following Allogeneic Stem Cell Transplantation after Reduced Intensity Conditioning for High-Risk AML. (2006) (0)
The BMT Data Book: Cellular therapy (2013) (0)
Treatment of Relapse of AML and MDS after Allogeneic Stem Cell Transplantation Using Low-Dose Chemotherapy, Donor PBSC and GM-CSF: Final Results from a Prospective, Multicenter Phase II Trial by the German Cooperative Transplant Group. (2007) (0)
Sequential Chemotherapy Followed by Reduced Intensity Conditioning and Allogeneic Stem Cell Transplantation (allo-SCT) in Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML): A Survey From the Acute Leukemia Working Party of EBMT (2012) (0)
Quality of Leukemia-Derived Dendritic Cells (DC) and T-Cells Are Predictive for the Specific Anti-Leukemic Potential of DC-Trained T-Cells. (2007) (0)
myeloid leukemia Drug treatment is superior to allografting as first-line therapy in chronic (2013) (0)
The destruction of contaminating tumor cells in stem cell with bispecific antibodies (1997) (0)
Single Stranded Polydeoxyribonucleotides Compete with the Incorporation of [ 3 H] Thymidine or [ 3 H]dAMP into DNA. (2005) (0)
Abstract A28: Donor lymphocyte infusion after allogeneic stem cell transplantation is a feasible therapy option with acceptable toxicity rates in patients with refractory Ewing’s sarcoma and rhabdomyosarcoma (2018) (0)
Treatment of Osteopenia/Osteoporosis after Allogeneic Hematological Cell Transplantation with Zoledronic Acid. (2006) (0)
Adoptive Immunotherapy of Acute Leukemia and Acute Phase Chronic Myeloid Leukemia after Allogeneic Bone Marrow Transplantation (2001) (0)
[Chemotherapy of chronic myelocytic leukemia. Status of the German Multicenter Study on busulfan versus hydroxyurea versus alpha interferon, October 1897]. (1988) (0)
PROSPECTIVE MULTICENTER STUDY FOR TREATMENT OF CHRONIC MYELOCYTIC-LEUKEMIA - COMPARISON OF BUSULFAN, HYDROCYUREA AND INTERFERON ALPHA (UPDATE APRIL, 1990) (1991) (0)
Adoptive Immunotherapy of p53-Mutated B-CLL with a Trifunctional Antibody (Anti-CD3 x Anti-CD20) and Allogeneic Donor Lymphocyte Transfusion. (2005) (0)
Faculty Opinions recommendation of Factors governing the activation of adoptively transferred donor T cells infused after allogeneic bone marrow transplantation in the mouse. (2007) (0)
Generation of Leukemia-Derived Dendritic Cells (DC leu ) as a Basis for Specific Immunotherapy in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS). (2004) (0)
Interferon-α in the Treatment of CML: Comparison of Busulfan versus Hydroxyurea versus Interferon-α (1994) (0)
Graft-Versus-Host Tolerance in Dogs Following T-Cell Depleted Bone Marrow Transplantation with Absorbed ATG or CD6-Antibody. (2008) (0)
[Bone marrow transplanation by aplastic anemia and acute leukemia--chances, success, indications (author's transl)]. (1977) (0)
Donor Cell Derived Leukemia: Description Of 38 Cases and a Case Control Study (2013) (0)
[Lethality in children with neuroblastoma (author's transl)]. (1981) (0)
Cellular immunity of allogeneic stem cell transplantation (2002) (0)
[Possibilities and problems of bone marrow transplantation in the therapy of acute leukemias (author' transl)]. (1981) (0)
The Pattern Of Cytogenetic Aberrations In CML BC Stratified For Treatment (2013) (0)
Immune Effects of Imatinib in Chronic Myelogenous Leukemia In Vitro. (2007) (0)
malignancies have potent antitumor activity against hematological and other Allorestricted T cells with specificity for the FMNL1-derived peptide PP2 (2013) (0)
Histopathology of hepatic acute graft-versus-host disease in the dog. [Gamma radiation] (1978) (0)
IFN-Alpha and gm-CSF Can Reverse Immunomodulatory Effects of Imatinib (2008) (0)
Immunohistochemical staining for differential diagnosis of cutaneous graft versus host disease and drug reactions (2007) (0)
Destroying contaminating tumor cells in stem cell transplants with bispecific antibodies (1996) (0)
[Influence of HLA-DR antigens on survival of allogeneic human kidney transplants (author's transl)]. (1980) (0)
Overexpression of the Metabolic Stress Sensor and Proglycolytic Transcription Factor ΜLΧΙΡ Mediates Malignancy of Common Acute Lymphoblastic Leukemia in Vivo and Is Targetable By Allorestricted Peptide Specific T Cells (2014) (0)
UTY-Coded Minor Histocompatibility Antigens as Targets for a Graft- Versus-Host Reaction against Hematopoietic Cells in the Dog. (2008) (0)
CD6-Depletion in the Dog Model: New Insights into Chimerism and Tolerance. (2007) (0)
Clinical and Genetic Risk Assessment for Overall Survival in Haematopoietic Stem Cell Transplantation (HSCT) (2009) (0)
Polydeoxyribonucleotides Antagonize Nucleoside Analogues in Cancer Therapy. (2006) (0)
Ultrastructure of neuraminidase-induced adhesion of lymphocytes to liver cells in vivo. Abstr. (1980) (0)
Subject Index Vol. 24,1997 (1997) (0)
Stem cell rescue from irradiation of multifocal bone disease combined with high-dose chemotherapy and reduced intensity conditioned haplodisparate stem cell transplantation in advanced pediatric sarcomas: Update of MetaEICESS 2007. (2014) (0)
Subject Index Vol. 111, 2004 (2004) (0)
Statistical modelling for clinical and genetic risk factors for GvHD and survival in a cohort of European HLA matched sibling transplants (2006) (0)
Rosai Dorfman's Disease with MAP2K1 Mutation Refractory to Chemotherapy with Complete Response to MEK Inhibitor Therapy: A Case Report (2022) (0)
Treatment of Steroid-Resistant Acute GvHD with OKT3 and High-Dose Steroids Versus High-Dose Steroids Alone. (2005) (0)
Using bi- and trispecific antibodies for the induction of tumor immunity (1997) (0)
P-016 Resistance to apoptosis in high-risk myelodysplastic syndrome can be overcome by pro-apoptotic drug treatment using ABT-737 (2013) (0)
Long-Term Results of Donor Lymphocyte Transfusions for the Treatment of Relapse After Allogeneic Transplantation for Chronic Myelogenous Leukemia - Is There a Role for Immunotherapy in CML?. (2009) (0)
Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia with Normal Karyotype: A Risk Factor Analysis in 247 Patients, Based On Molecular Markers and Stage at Transplantation. (2009) (0)
Discontinued at Least 90 Days Before the Procedure Myelogenous Leukemia Does Not Affect Outcome Adversely, Provided It Is Interferon-? Before Allogeneic Bone Marrow Transplantation in Chronic (2013) (0)
Quantitative Monitoring By RT-PCR of Molecular Markers on Day +100 after Allogeneic Stem Cell Transplantation Predicts Outcome in Patients with Acute Myeloid Leukemia (2014) (0)
The GVL Effect in Donor Lymphocyte Transfusion (2000) (0)
[Clinical aspects of Menkes syndrome]. (1987) (0)
A method for ex vivo immunization using intact heterologous bispecific and / or trispecific antibodies (1997) (0)
A method for ex vivo immunization using intact heterologous divalent and / or trivalent antibodies (1998) (0)
Allogeneic Transplantation in Elderly Patients with AML and MDS Comparing Reduced-Intensity Conditioning with Flamsa-Busulfan Versus Fludarabine/BCNU/Melphalan (2014) (0)
Immunomodulatory Effects of STI571 in Chronic Myeloid Leukaemia. (2006) (0)
Bone Marrow Reaction in Chronic Graft-Versus-Host Disease. (2008) (0)
[Bone marrow transplantation for aplastic anaemia (author's transl)]. (1981) (0)
[Multicenter prospective controlled study of therapy of chronic myeloid leukemia. Comparison of busulfan, hydroxyurea and interferon alpha (April 1990 status)]. (1991) (0)
Monitoring the Antileukemic Immune Response with an Active Specific Immunization Strategy (2012) (0)
Dmg treatment is superior to allografting as first-line therapy in chronic myeloid leukemia. Commentary (2007) (0)
[Organ tolerance and incomplete bone marrow chimera in dogs]. (1977) (0)
Rejection of Primary Lymphoma Cells Derived from c-myc-Transgenic Mice after Haploidentical Transplantation: Treatment of the Tumor May Confer to Resistance Against GvL-Effect. (2005) (0)
High age and high frequency of treatment switch in CML patients outside of clinical trials: interim results of the German CML VI trial (2017) (0)
Original Research Report Endothelial Cells but Not Epithelial Cells or Cardiomyocytes Are Partially Replaced by Donor Cells after Allogeneic Bone Marrow and Stem Cell Transplantation (2003) (0)
Immunotherapy of Acute MYELOID LEUKEMIA: ANTI-LEUKEMIC EFFECTS by Unprimed or Primed, Selected or Unselected Effector T-CELLS. (2009) (0)
Retracted Chapter: Akute Graft-versus-Host-Reaktion: Therapie mit extrakorporaler Photopherese (1997) (0)
Proteomic screening applied to the diagnosis of chronic graft-versus-host disease (2010) (0)
Related Versus Unrelated Donor Transplantation for High Risk (HiRi) Acute Myeloid Leukemia (AML) in First Complete Remission (CR1). (2007) (0)
The delta Assay - A Suitable Tool To Detect the Cellular Immune Response Against Acute Myeloid Leukemia Blasts. (2005) (0)
[Etiology, variety of form and clinical aspects of neural tube defects]. (1991) (0)
Major Route Additional Chromosomal Aberrations (ACA) Precede Increase of Blasts in CML: An Analysis of the German CML-Studies III and IIIA (2015) (0)
Clofarabine Containing Conditioning Regimen for Allo-SCT in AML/ALL Patients: A Survey From the Acute Leukemia Working Party of EBMT (2011) (0)
Allogeneic Rejection of High Grade Lymphoma: Evidence for Immune Escape in a Haploidentical Murine Model. (2006) (0)
Obituary. In memoriam Stefan Thierfelder. (2010) (0)
A novel nonradioactive CFDA assay to monitor the cellular immune response in myeloid leukemia. (2013) (0)
Relevance of the Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI) On Non-Relapse Related Mortality (NRM) in Patients with Acute Lymphoblastic Leukemia (ALL) Receiving Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in First Complete Remission: Results From the GMALL S (2009) (0)
Acute heart failure: when standard therapy fails--an interdisciplinary challenge. (2011) (0)
Bone Marrow Contains High Levels of Microparticles (2014) (0)
photopheresis for treatment of chronic graft-versus-host disease A multicenter prospective phase 2 randomized study of extracorporeal (2013) (0)
Absolute BCR-ABL Transcript Levels At 3 Months but Not At Diagnosis Predict Survival of Chronic Myeloid Leukemia (CML) Patients On Imatinib Therapy (2012) (0)
A process for the preparation of cell preparations for the immunization by means of heterologous intact bispecific and / or trispecific antibodies (1997) (0)
Leukemia-Derived DC for T-Cell Therapy against AML Progenitor Cells (2008) (0)
Bone Marrow Transplantation in Aplastic Anaemia (1974) (0)
Exogenous Nucleic Acids - A Potential Source of Resistance to Nucleoside Analogues in Cancer and Antiviral Therapy. (2007) (0)
Su.1. Promising Results of Adjuvant Donor Lymphocyte Transfusions Following Allogeneic Stem Cell Transplantation After Reduced Intensity Conditioning for High-Risk Aml (2006) (0)
Faculty Opinions recommendation of Donor lymphocyte infusions for the treatment of minimal residual disease in acute leukemia. (2007) (0)
Immunotherapy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation: study protocol of an investigator-driven, open-label, non-randomized, uncontrolled, dos (2013) (0)
[Steroid-refractory graft-versus-host disease: extracorporeal irradiation of leucocytes induces immunotolerance]. (2009) (0)
Proteomic Screening Applied to the Diagnosis of Chronic Graft-Versus-Host-Disease. (2009) (0)
Drug treatment or stem cell transplantation as primary treatment for patients with CML (2007) (0)
Therapeutic Plasma Levels of OKT3 Muromonab Are Effective as Second-Line and Subsequent Treatment in Recipients of Stem Cell Allografts with Steroid-Resistant Acute Graft-Versus-Host Disease. (2004) (0)
Y-Chromosome Genes Strongly Expressed in Acute Myeloid Leukaemia. (2007) (0)
[Prospective controlled study of therapy of chronic myeloid leukemia (CML)]. (1987) (0)
A Comparison of Acute GVHD after HLA-Haploidentical and HLA-Identical Stem Cell Transplantation. (2004) (0)
Characterization of CD6-Negative Suppressor Cells Facilitating HLA-Haploidentical Stem Cell Transplantation. (2005) (0)
Adoptive Immunotherapy: Guidelines and Clinical Practice (2006) (0)
Donor Lymphocyte Transfusion (DLT) in the Treatment of Relapsed CML after Allogeneic PBSCT - A Retrospective Analysis of 346 Patients by the EBMT Chronic Leukemia Working Party. (2005) (0)
Efficacy of repeat myeloablative chemotherapy with autologous stem-cell support in multiple myeloma (2012) (0)
Host Interferon gamma Production and STAT-1 Signalling Is Crucial for Minor Antigen Mediated Rejection of High Grade Lymphoma. (2007) (0)
Contents Vol. 111, 2004 (2004) (0)
Ten-year survival after randomized comparison of imatinib (IM) 400 mg vs. IM 800 mg vs. IM + IFN vs. IM + Ara C vs. IM after IFN in chronic myeloid leukemia (CML). (2017) (0)
Prospective Evaluation of a GvHD-Specific Proteom Pattern. (2004) (0)
Stem cell rescue from irradiation of multiple tumor sites combined with high-dose chemotherapy, followed by reduced intensity conditioning and allogeneic stem cell transplantation in patients with advanced pediatric sarcomas: Preliminary results of the MetaEICESS 2007 protocol. (2015) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Hans-jochem Prof Dr Kolb?

Hans-jochem Prof Dr Kolb is affiliated with the following schools:

Hans-jochem Prof Dr Kolb's Academic­Influence.com Rankings

Why Is Hans-jochem Prof Dr Kolb Influential?

Hans-jochem Prof Dr Kolb's Published Works

Published Works

What Schools Are Affiliated With Hans-jochem Prof Dr Kolb?

Hans-jochem Prof Dr Kolb's AcademicInfluence.com Rankings